Chinese Academy of

This Phase 2 investigator-initiated trial (IIT2024067) evaluates a triple-agent combination of ivosidenib, venetoclax, and azacitidine for acute myeloid leukemia (AML), sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences. The program combines three small-molecule antineoplastic agents with established clinical activity in AML: azacitidine (a hypomethylating agent approved globally), venetoclax (a BCL-2 inhibitor), and ivosidenib (an IDH1 inhibitor). The trial is currently active with a latest milestone dated 13 May 2026. Azacitidine has extensive regulatory approval across Australia, Europe, and the United States, with multiple manufacturers and PBS listings in Australia. The combination approach represents a strategy to enhance efficacy in AML through synergistic mechanisms, though specific efficacy and safety data from this trial remain not yet disclosed. The program's development status indicates ongoing patient enrollment or data collection as of the latest milestone date.

Acute myeloid leukemia remains a serious hematologic malignancy with significant unmet medical need, particularly in elderly patients and those with specific molecular subtypes. The combination of a hypomethylating agent (azacitidine), a BCL-2 inhibitor (venetoclax), and an IDH1 inhibitor (ivosidenib) targets multiple pathogenic pathways implicated in AML pathogenesis and chemotherapy resistance. This triple-agent approach may address limitations of dual-agent combinations by providing enhanced disease control and potentially overcoming mechanisms of resistance. The trial's focus on this specific combination reflects emerging evidence that synergistic targeting of epigenetic dysregulation, apoptotic evasion, and metabolic alterations can improve outcomes in AML. Market relevance is substantial given the aging global population and increasing AML incidence; azacitidine alone has achieved widespread adoption across major markets. The competitive landscape includes established therapies such as venetoclax-azacitidine combinations and IDH inhibitor monotherapies, making differentiation through triple-agent synergy strategically important. Patient population encompasses both newly diagnosed and relapsed/refractory AML cases, representing a substantial addressable market with significant commercial potential if efficacy and tolerability are demonstrated.

Drug Class: Antineoplastic and immunomodulating agents (ATC L01). The program combines three distinct small-molecule agents with complementary mechanisms in hematologic malignancy.

• Azacitidine (AZACITIDINE ACCORD): Hypomethylating agent; oral route of administration; approved in Australia (PBS codes 12771E, 12784W, 13028Q, 13033Y, 13036D, 13038F, 13039G, 13040H, 13042K, 13044M), Europe (multiple EMA product numbers including EMEA/H/C/000978), and United States (NDA050794, NDA208216, NDA214120); multiple manufacturers including Accord Healthcare, Bristol-Myers Squibb, Dr Reddy's, and others.
• Venetoclax: BCL-2 inhibitor; mechanism targets apoptotic evasion in leukemic cells; approved globally for AML in combination with hypomethylating agents.
• Ivosidenib: IDH1 inhibitor; targets isocitrate dehydrogenase 1 mutations present in subset of AML cases; approved for IDH1-mutant AML.

Modality: Small-molecule oral combination therapy. Route: Oral administration for azacitidine component. Related Therapies: Venetoclax-azacitidine dual combinations represent current standard of care in many AML populations; IDH inhibitors as monotherapy or in combination represent alternative approaches.

Azacitidine Regulatory Status:

• Australia (TGA): Approved; multiple PBS listings with codes 12771E, 12784W, 13028Q, 13033Y, 13036D, 13038F, 13039G, 13040H, 13042K, 13044M; multiple sponsors including Accord Healthcare Pty. Ltd., Bristol-Myers Squibb Australia Pty Ltd, Dr Reddy's Laboratories (Australia) Pty Ltd, EUGIA PHARMA (AUSTRALIA) PTY LTD, and Juno Pharmaceuticals Pty Ltd; first listed dates from 01 August 2017 onwards.
• European Union (EMA): Approved; multiple marketing authorization holders including Accord Healthcare S.L.U., Bristol-Myers Squibb Pharma EEIG, Celgene Europe BV, Fresenius Kabi Deutschland GmbH, Mylan Pharmaceuticals Limited, and betapharm Arzneimittel GmbH; EMA product numbers include EMEA/H/C/000978, EMEA/H/C/004761, EMEA/H/C/004984, EMEA/H/C/005075, EMEA/H/C/005147, EMEA/H/C/005300, and EMEA/H/C/006154; authorization dates from 12 December 2025 onwards.
• United States (FDA): Approved; multiple ANDA approvals (generic formulations) including ANDA201537, ANDA204949, ANDA207234, ANDA207475, ANDA207518, ANDA209337, ANDA209540, ANDA210748, ANDA211549, ANDA212128, ANDA212580, ANDA215066, ANDA215765, ANDA215905, ANDA217453, ANDA218751; original NDA050794 and additional NDAs NDA208216 and NDA214120; multiple sponsors including Accord Healthcare, Actavis, Amneal, Bristol-Myers, Cipla, Dr Reddy's, and others.
• China (NMPA): Clinical trials status; multiple ongoing trials including NCT05140811, NCT05144243, NCT05675813, NCT06386302, and NCT06449482.

Combination Program (IIT2024067): Regulatory status of the triple-agent combination not yet disclosed; trial is investigator-initiated and currently active in China.

Strategic Implications: The investigator-initiated trial structure suggests academic-led development of a combination strategy that may not be the primary focus of commercial sponsors. This approach allows for rapid evaluation of synergistic combinations without requiring formal licensing agreements, potentially accelerating clinical data generation. The Phase 2 status indicates early-stage efficacy and safety evaluation; progression to Phase 3 would require demonstration of meaningful clinical benefit.

Competitive Implications: If the triple-agent combination demonstrates superior efficacy to current dual-agent standards (venetoclax-azacitidine), it could reshape treatment paradigms in AML. However, increased toxicity or complexity could limit adoption. The combination leverages three well-established agents with known safety profiles, reducing development risk compared to novel compounds. Commercial viability depends on demonstrating clinically meaningful improvements in complete remission rates, overall survival, or duration of response.

Future Catalysts: Primary catalysts include Phase 2 efficacy and safety data readout (expected timing not disclosed), potential Phase 3 initiation if warranted by Phase 2 results, and regulatory feedback from NMPA regarding combination therapy approval pathway. Additional catalysts include publication of trial results in peer-reviewed journals and potential adoption by academic medical centers in China and internationally.

Expected Milestones: Specific next milestone timing is not yet disclosed. Typical Phase 2 AML trials require 2-3 years for enrollment and follow-up; data readout could be anticipated in 2027-2028 timeframe, though this is not confirmed by available facts.